Zacharias G. Laoutidis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zacharias G. Laoutidis has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
A. Konstantinidis
Department of Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Vienna, Austria
1 shared publicationC. Luckhaus
Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
1 shared publicationGeorgia E. Lekka
Department of Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty of the Heinrich Heine University, Düsseldorf, Germany
1 shared publicationJ. Cordes
Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
1 shared publicationJ. Mobascher
Department of Psychiatry and Psychotherapy, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
1 shared publicationKanellos T. Kioulos
Eginition Hospital, 1st Department of Psychiatry, Medical Faculty, University of Athens, Greece
1 shared publication
Latest Publications
- 25 October 2016
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 77 (12) , e1576-e1583
Glutamatergic Agents as Add-On Medication for the Treatment of Obsessive-Compulsive Disorder
The aim of the present study was to review the existing literature on clinical trials with glutamatergic agents in adults with obsessive-compulsive disorder (OCD) and to perform a meta-analysis to estimate the overall effect size. We searched in MEDLINE, Embase, and the Cochrane Library for eligible studies, using the following search terms: (glutamate OR glutaminergic OR glutamatergic OR NMDA OR AMPA OR kainate) AND (obsessive-compulsive disorder OR obsessive OR compulsive OR OCD). A separate search was performed for generally known glutamatergic agents. The databases were searched for articles published by May 31, 2015. Eligible studies were double-blind, randomized controlled trials that tested the efficacy of add-on treatment with a glutamatergic agent in patients with OCD. Data were extracted independently by 2 reviewers. We extracted dichotomous data (number of patients with response and remission) to estimate relative risk ratios (RRs), as well as continuous data (scores in Yale-Brown Obsessive Compulsive Scale and Clinical Global Impressions-Severity of Illness and -Improvement scales), which were used to estimate standardized mean differences. Effect sizes were estimated using a random-effects model. Eight randomized controlled trials were identified. The overall ratio for response was RR = 3.71 (95% CI, 2.35-5.83; P < .001). When limited to the studies with treatment-resistant patients, the effect size remained significant (RR = 4.30; 95% CI, 2.19-8.43; P < .001). Secondary outcomes, such as the standardized mean differences for continuous data, showed the statistically significant superiority (P < .001) of glutamatergic agents over placebo. The risk of dropouts was RR = 1.18 (95% CI, 0.83-1.69; P = .361) and the risk of dropouts due to adverse effects was RR = 3.04 (95% CI, 1.57-5.89; P = .001). Glutamatergic agents are effective as add-on treatment for OCD in general and especially for treatment-refractory OCD.
- 25 October 2016
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 77 (12) , e1576-e1583
Glutamatergic Agents as Add-On Medication for the Treatment of Obsessive-Compulsive Disorder
The aim of the present study was to review the existing literature on clinical trials with glutamatergic agents in adults with obsessive-compulsive disorder (OCD) and to perform a meta-analysis to estimate the overall effect size. We searched in MEDLINE, Embase, and the Cochrane Library for eligible studies, using the following search terms: (glutamate OR glutaminergic OR glutamatergic OR NMDA OR AMPA OR kainate) AND (obsessive-compulsive disorder OR obsessive OR compulsive OR OCD). A separate search was performed for generally known glutamatergic agents. The databases were searched for articles published by May 31, 2015. Eligible studies were double-blind, randomized controlled trials that tested the efficacy of add-on treatment with a glutamatergic agent in patients with OCD. Data were extracted independently by 2 reviewers. We extracted dichotomous data (number of patients with response and remission) to estimate relative risk ratios (RRs), as well as continuous data (scores in Yale-Brown Obsessive Compulsive Scale and Clinical Global Impressions-Severity of Illness and -Improvement scales), which were used to estimate standardized mean differences. Effect sizes were estimated using a random-effects model. Eight randomized controlled trials were identified. The overall ratio for response was RR = 3.71 (95% CI, 2.35-5.83; P < .001). When limited to the studies with treatment-resistant patients, the effect size remained significant (RR = 4.30; 95% CI, 2.19-8.43; P < .001). Secondary outcomes, such as the standardized mean differences for continuous data, showed the statistically significant superiority (P < .001) of glutamatergic agents over placebo. The risk of dropouts was RR = 1.18 (95% CI, 0.83-1.69; P = .361) and the risk of dropouts due to adverse effects was RR = 3.04 (95% CI, 1.57-5.89; P = .001). Glutamatergic agents are effective as add-on treatment for OCD in general and especially for treatment-refractory OCD.
- 18 May 2015
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 48 (04/05) , 178-181
Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project
The elevation of creatine kinase (CK) levels without neuroleptic malignant syndrome has been reported for several antipsychotics. We present here 4 cases with CK elevation induced by amisulpride, which have been registered for the German pharmacovigilance project, Arzneimittelsicherheit in der Psychiatrie (AMSP). The magnitude of the CK elevation ranged between 1 498 IU/L and 21 018 IU/L. All 4 patients reported myalgia. In each case CK returned to normal after amisulpride discontinuation. In the fourth case, fluids were administered intravenously in order to prevent acute renal failure. None of the cases showed deterioration of renal function. Finally, we present recommendations for clinical practice.
- 18 May 2015
- Published by Georg Thieme Verlag KG in Pharmacopsychiatry
- Vol. 48 (04/05) , 178-181
Reversible Amisulpride-induced Elevation of Creatine Kinase (CK): A Case Series from the German AMSP Pharmacovigilance Project
The elevation of creatine kinase (CK) levels without neuroleptic malignant syndrome has been reported for several antipsychotics. We present here 4 cases with CK elevation induced by amisulpride, which have been registered for the German pharmacovigilance project, Arzneimittelsicherheit in der Psychiatrie (AMSP). The magnitude of the CK elevation ranged between 1 498 IU/L and 21 018 IU/L. All 4 patients reported myalgia. In each case CK returned to normal after amisulpride discontinuation. In the fourth case, fluids were administered intravenously in order to prevent acute renal failure. None of the cases showed deterioration of renal function. Finally, we present recommendations for clinical practice.
- 16 October 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (22) , 4255-4270
Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice
The primary antipsychotic-induced creatine kinase elevation (i.e., not due to neuroleptic malignant syndrome, extrapyramidal symptoms, etc.) is a poorly studied condition. The aims of the present study were to provide an overview of published cases with antipsychotic-induced creatine kinase elevation and give recommendations for the clinical practice. PubMed and EMBASE were searched for eligible trials, case series, and case reports. We set a threshold at ten times the upper normal limit of the creatine kinase value in order to define an elevation as significant. The prevalence of significant creatine kinase elevation ranged between 2 and 7 %. We found a total of 42 eligible cases. Men were overrepresented in our sample (81 %). Patients with myoglobinuria were more likely to be symptomatic (Fisher’s exact test, p = 0.006), whereas neither myoglobinuria (Mann-Whitney test, p > 0.10) nor symptoms (Mann-Whitney test, p = 0.64) were related to the magnitude of the creatine kinase (CK) elevation. In the majority of the cases, the antipsychotic medication was discontinued (86 %). Forced diuresis was given in 36 % of the patients. Eighty-three percent of the patients had no further complications. Only one case was found with a de novo acute renal failure. The discontinuation of the antipsychotic medication was a sufficient measure for the CK elevation to subside in the majority of the cases. Cases with myoglobinuria should eventually be treated more aggressively. Further recommendations for the clinical practice are presented.
- 16 October 2014
- Published by Springer Nature in Psychopharmacology
- Vol. 231 (22) , 4255-4270
Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice
The primary antipsychotic-induced creatine kinase elevation (i.e., not due to neuroleptic malignant syndrome, extrapyramidal symptoms, etc.) is a poorly studied condition. The aims of the present study were to provide an overview of published cases with antipsychotic-induced creatine kinase elevation and give recommendations for the clinical practice. PubMed and EMBASE were searched for eligible trials, case series, and case reports. We set a threshold at ten times the upper normal limit of the creatine kinase value in order to define an elevation as significant. The prevalence of significant creatine kinase elevation ranged between 2 and 7 %. We found a total of 42 eligible cases. Men were overrepresented in our sample (81 %). Patients with myoglobinuria were more likely to be symptomatic (Fisher’s exact test, p = 0.006), whereas neither myoglobinuria (Mann-Whitney test, p > 0.10) nor symptoms (Mann-Whitney test, p = 0.64) were related to the magnitude of the creatine kinase (CK) elevation. In the majority of the cases, the antipsychotic medication was discontinued (86 %). Forced diuresis was given in 36 % of the patients. Eighty-three percent of the patients had no further complications. Only one case was found with a de novo acute renal failure. The discontinuation of the antipsychotic medication was a sufficient measure for the CK elevation to subside in the majority of the cases. Cases with myoglobinuria should eventually be treated more aggressively. Further recommendations for the clinical practice are presented.